Scientists at MIT and Recursion Pharmaceuticals launched Boltz-2, an AI-driven open-source platform that predicts small-molecule binding affinities with improved accuracy. This breakthrough addresses a fundamental bottleneck in drug discovery by enabling rapid, reliable prediction of protein-ligand interactions and biomolecular complex structures. The model's public release invites broader scientific collaboration to accelerate therapeutic development and molecular design.